6.1.1. The underlying growth in the global pharma market (Table 4) and the global generics market (Table 5), combined with a continued trend toward outsourcing, is driving growth in the global CDMO market (Table 17). APIs represent over half of the pharmaceutical market, and so it follows that growth of the global API CDMO market (Table 18) will align with the larger CDMO market. Growth of the global OSD CDMO market is slightly flatter (Table 19), but still represents a healthy, growing industry.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
6.2.1. As of 2020, about half of all Americans were taking at least one prescription,[94] and 70% of those prescriptions were dispensed as tablets.[12] Within the OSD CDMO landscape, traditional tablet manufacturing is expected to continue growing, especially with the acquisition of advanced capabilities that incorporate such features as high-speed presses, in-line monitoring, and continuous manufacturing features. Advanced tablet dosage forms such as multilayer tablets, ODTs, and chewables will continue to gain market share.[29]
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
6.3.1. While popular discussions in the U.S. focus on reshoring of pharmaceutical manufacturing, most of these efforts apply only to API manufacturing. The United States has historically been and remains the dominant player in OSD or final dosage form manufacturing. While the Asia–Pacific (APAC) region accounts for 36.6% of the $41 billion global OSD CDMO market (Figure 12), the U.S. dominates the market with 26.8% of the global market share, which was over $11 billion in 2023 (Figure 13). Compare this distribution with the distribution of API CDMOs globally (Figure 14). We can only conclude that, while drug manufacturers seek overseas API manufacturing capacity owing to lower costs, the preference remains to onshore the bulk material for OSD processing within the U.S., which remains the largest single pharmaceutical market.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.
6.4.1. Wet granulation methods of various types are predominant in the industry. According to one survey, 38% of all tablet and capsule formulations incorporated wet granulation, and 61% of formulations with fine API used the technology. Wet granulation is often used for APIs with poor flowability characteristics and to achieve higher drug loadings. Continuous manufacturing (CM) is becoming more prevalent in the industry, and the FDA confirmed that between 2015 and 2022, CM enabled five different OSD products to reach the market four to 12 months sooner than would have been possible with batch processing. The $170–500M revenue benefit per drug will certainly continue to drive adoption of the technology within the industry.[69] Sales forecasts for some drugs manufactured by CM are presented in Table 14.
Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.Nice Insight provides customers with the latest trends in the market, hard-to-find pricing, and analysis of important scientific innovation and challenges. Our research reports help innovators understand the price they'll pay for a contractor and what challenges they should anticipate, and allow CDMOs to evaluate their position in the market.